Laboratories Abbott Product... Net Worth

The estimated Net Worth of Laboratories Abbott Product... is at least $2.24 mil millones dollars as of 23 March 2017. Laboratories Product owns over 44,000,000 units of Mylan NV stock worth over $408,137,500 and over the last 8 years Laboratories sold MYL stock worth over $1,830,400,000.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Laboratories Product MYL stock SEC Form 4 insiders trading

Laboratories has made over 1 trades of the Mylan NV stock since 2017, according to the Form 4 filled with the SEC. Most recently Laboratories sold 44,000,000 units of MYL stock worth $1,830,400,000 on 23 March 2017.

The largest trade Laboratories's ever made was selling 44,000,000 units of Mylan NV stock on 23 March 2017 worth over $1,830,400,000. On average, Laboratories trades about 44,000,000 units every 0 days since 2017. As of 23 March 2017 Laboratories still owns at least 25,750,000 units of Mylan NV stock.

You can see the complete history of Laboratories Product stock trades at the bottom of the page.

Insiders trading at Mylan NV

Over the last 10 years, insiders at Mylan NV have traded over $1,861,785,794 worth of Mylan NV stock and bought 202,008 units worth $5,767,632 . The most active insiders traders include Laboratories Abbott Product..., Daniel Martin Jr Gallagher y Robert J Coury. On average, Mylan NV executives and independent directors trade stock every 15 days with the average trade being worth of $5,605,891. The most recent stock trade was executed by Robert J Cindrich on 16 November 2020, trading 9,440 units of MYL stock currently worth $149,624.

What does Mylan NV do?

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Complete history of Laboratories Product stock trades at Mylan NV

Mylan NV executives and stock owners

Mylan NV executives and other stock owners filed with the SEC include:

• Heather Bresch,
  Chief Executive Officer, Executive Director
• Rajiv Malik,
  President, Executive Director
• Robert Coury,
  Executive Chairman of the Board
• Mark Parrish,
  Lead Independent Non-Executive Vice Chairman of the Board
• JoEllen Dillon,
  Non-Executive Independent Director
• Neil Dimick,
  Non-Executive Independent Director
• Melina Higgins,
  Non-Executive Independent Director
• Sjoerd Vollebregt,
  Non-Executive Independent Director
• Robert Cindrich,
  Non-Executive Independent Director
• Harry Korman,
  Non-Executive Independent Director
• Randall Vanderveen,
  Non-Executive Independent Director
• Pauline van der Meer Mohr,
  Non-Executive Independent Director
• Richard Mark,
  Non-Executive Independent Director
• Melissa Trombetta,
  Head of Global Investor Relations
• Joseph C Md Maroon,
  Director
• Rodney L Piatt,
  Director
• Paul Campbell,
  See Remarks
• Laboratories Abbott Product...,
  
• Kenneth Scott Parks,
  Chief Financial Officer
• Wendy Cameron,
  Director
• Douglas J Leech,
  Director
• Daniel Martin Jr Gallagher,
  Chief Legal Officer
• Anthony Mauro,
  Chief Commercial Officer
• John D Sheehan,
  EVP and CFO
• Laboratories Abbott Establi...,
  
• Laboratories Laboratoires F...,